MLYS · Mineralys Therapeutics, Inc.

$27.52 +0.81 (+3.03%) At close · Jul 21

Market Cap

$2.27B

82.50M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jon Congleton	CEO	$636,500	—	—	$4,435,626	$472,601	—	$5,544,727
David Rodman	CMO	$533,000	$25,000	—	$1,322,906	$323,798	—	$2,204,704
Adam Levy	CFO	$532,000	$25,000	—	$1,322,906	$323,190	—	$2,203,096

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jon Congleton	CEO	$580,000	—	—	$4,537,818	$303,050	—	$5,420,868
David Rodman	CMO	$520,000	—	—	$2,135,449	$222,300	—	$2,877,749
Adam Levy	CFO	$500,000	—	—	$2,135,450	$213,750	—	$2,849,200

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jon Congleton	CEO	$517,000	—	—	$4,579,482	$245,575	—	$5,342,057
David Rodman	CMO	$500,000	—	—	$1,620,457	$213,750	—	$2,334,207
Adam Levy	CFO	$450,000	$21,375	—	$1,533,806	$171,000	—	$2,176,181

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jon Congleton	CEO	$416,667	$72,450	$1,118,118	—	$120,750	$12,200	$1,740,185
David Rodman	CMO	$411,458	$71,544	—	$492,064	$119,241	$12,200	$1,106,507
Adam Levy	CFO	$334,926	—	$483,500	—	$190,900	$7,262	$1,016,588

Key facts CIK 1933414 CUSIP 603170101 13F (30d) 13 filings 13 filers Visit website Investor relations